# CanadaBuys #20175646

Genomic hybridization microarrays and reagent kits for the CHUL diagnostic platform

**Posted:** October 13, 2026
**Respond By:** October 24, 2026
**Identifier:** 20175646
**NAICS:** 325413

Santé Québec’s CHU de Québec–Université Laval is seeking genomic hybridization microarrays and related reagents for the CHUL molecular diagnostic laboratory.
- **Proposed supplier and OEM:** Revvity Health Sciences Canada, inc. is the intended direct-award supplier; the products must work with the existing **Agilent SureScan** scanner and Genoglyphix software.
- **Requested products:**
  - CGH 4plex-HD Microarray — GRM 793249; non-SNP, 4x180k format, four samples per slide, and at least 180,000 probes per sample.
  - 4plex Microarray Hybridization Kit — GRM 793250; stated capacity of 100 patients.
  - 4plex Microarray DNA-Labeling Kit — GRM 793251; stated capacity of 25 patients.
  - CGX Oligo aCGH Wash Solutions — GRM 793260; stated capacity of 160 patients.
  - Human Cot-1 DNA — GRM 793261; stated capacity of 125 patients.
  - CGX HD/SNP-100 Microarray Seal — GRM 793262.
  - Patient capacities are product descriptions, not specified order quantities.
- **Key requirements:** Validated human oligonucleotide design; specified genome-wide and syndromic-region resolution; detection of more than 200 microdeletion/microduplication regions and coverage of more than 900 clinically relevant genes. The solution must support secure remote analysis with activity traceability, automated reporting, and integration with ClinVar, DGV, Decipher, and OMIM.
- **Delivery and support:** At least six months of shelf life on delivery, delivery within six weeks, dry-ice shipment for frozen products, technical support within 48 hours, documentation and ongoing training, and guaranteed Canadian buffer stock.
- **Procurement context:** The organization cites continuity with its validated platform and historical database, and the risks and costs of changing suppliers, as reasons for the proposed direct award. It may withdraw that intention and proceed with a public tender if a legally admissible expression of interest demonstrates the ability to meet the requirements.
- **Period:** Estimated duration is 36 months; start and end dates are not specified.

### Description

Santé Québec - CHU de Québec - Université Laval intends to award a sole-source contract to Revvity Health Sciences Canada, inc. for kits and microarrays used by the CHUL molecular diagnostic laboratory’s genomic hybridization platform. The listed products include CGH microarrays, hybridization and DNA-labeling kits, wash solutions, human Cot-1 DNA, and microarray seals. Requirements include compatibility with the existing Agilent SureScan scanner and Genoglyphix software, specified analytical resolution and detection capacity, secure remote analysis, automated reporting and database integration, and delivery, support, training, and Canadian buffer-stock provisions. The notice invites expressions of interest by October 23, 2026; if a qualified and legally admissible expression is received, the organization says it will withdraw the direct-award intention and proceed with a public tender.

[View original listing](https://canadabuys.canada.ca/en/tender-opportunities/tender-notice/qc20175646)